DCA + Temodal + radioterapia - badania klinczne -Faza I
Napisane: Cz lip 10, 2008 7:27 pm
Combining Radiotherapy and Temozolomide With Dichloracetate in Patients With Newly Diagnosed Glioblastoma
(tylko dawka DCA zdecydowanie za mala - 3mg/kg)
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study
Official Title: A Phase I Single Arm Trial Combining Radiotherapy and Temozolomide With Dichloracetate (DCA) in Patients With Newly Diagnosed Glioblastoma Multiform Tumours
Further study details as provided by Alberta Cancer Board:
Primary Outcome Measures:
* Safety and tolerability of DCA in combination with radiotherapy and temozolomide in an adjuvant setting for the treatment of newly diagnosed GBM patients. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
* To determine if there is a correlation between MGMT promoter methylation status and progression-free survival for newly diagnosed GBM patients undergoing concurrent TMZ, DCA and RT followed by six monthly cycles of TMZ and DCA [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Estimated Enrollment: 15
Study Start Date: July 2008
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Intervention Details:
Drug: Dichloroacetate (DCA)
DCA starting at an initial dose of 3mg/kg twice daily PO for consecutive days (days 1-5) on a 28 days cycle up to 6 cycles unless evidence of tumour progression. Each dose to be administered with food at the same time everyday 12 hours apart.
Detailed Description:
Patients with newly diagnosed Glioblastoma Multiforme Tumours, once consented to the study, would undergo standard treatment of radiotherapy plus chemotherapy (TMZ) with DCA in pill form (twice a day) during the radiation phase of the study and then with TMZ for six months after. Other elements of the clinical trial include pharmacokinetics and MGMT genetic testing.
(tylko dawka DCA zdecydowanie za mala - 3mg/kg)
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study
Official Title: A Phase I Single Arm Trial Combining Radiotherapy and Temozolomide With Dichloracetate (DCA) in Patients With Newly Diagnosed Glioblastoma Multiform Tumours
Further study details as provided by Alberta Cancer Board:
Primary Outcome Measures:
* Safety and tolerability of DCA in combination with radiotherapy and temozolomide in an adjuvant setting for the treatment of newly diagnosed GBM patients. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
* To determine if there is a correlation between MGMT promoter methylation status and progression-free survival for newly diagnosed GBM patients undergoing concurrent TMZ, DCA and RT followed by six monthly cycles of TMZ and DCA [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Estimated Enrollment: 15
Study Start Date: July 2008
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Intervention Details:
Drug: Dichloroacetate (DCA)
DCA starting at an initial dose of 3mg/kg twice daily PO for consecutive days (days 1-5) on a 28 days cycle up to 6 cycles unless evidence of tumour progression. Each dose to be administered with food at the same time everyday 12 hours apart.
Detailed Description:
Patients with newly diagnosed Glioblastoma Multiforme Tumours, once consented to the study, would undergo standard treatment of radiotherapy plus chemotherapy (TMZ) with DCA in pill form (twice a day) during the radiation phase of the study and then with TMZ for six months after. Other elements of the clinical trial include pharmacokinetics and MGMT genetic testing.